Scinai Immunotherapeutics (SCNI) investor relations material

Strategic positioning and leadership

• Proprietary NanoAb platform and pipeline target large markets with high unmet needs, including psoriasis and rare skin disorders.

• Dual revenue streams from innovative therapeutics and a growing US-based CDMO business help mitigate financial risk.

• Leadership and board bring deep pharma, biotech, and operational expertise from global companies.

• Collaborations with Max Planck Society and UMG enhance discovery and characterization of NanoAbs.

NanoAb platform and therapeutic pipeline

• NanoAbs (VHH antibodies) offer advantages over traditional mAbs: higher API yield, faster/cheaper production, and improved stability.

• Lead asset targets mild to moderate psoriasis, addressing a $10B+ market and underserved patient population.

• Intradermal anti-IL-17 NanoAb shows strong preclinical efficacy, with plans for first-in-human trials in 2026.

• Second asset, fully human anti-FasL mAb (PC111), targets pemphigus and SJS/TEN, both with high unmet needs and billion-dollar market potential.

• Positive proof-of-concept data in both lead indications, with patent protection and orphan drug designations.

Market need and CDMO business

• Biologics CDMO market projected to grow from $19.8B in 2024 to $84.9B by 2034 at a 15.7% CAGR.

• Scinai is the only local provider in Israel offering fermentation-based CDMO services and protein purification.

• End-to-end services include process development, analytical methods, GMP/non-GMP manufacturing, QC, and fill/finish.

• State-of-the-art cGMP facility in Jerusalem meets FDA/EMA standards, with single-use equipment for flexible, rapid production.

• CDMO business generates near-term revenue and de-risks internal R&D investments.